Defence Therapeutics Inc., a known biotechnology company brilliantly working and sharpening its focus on next-generation antibody-drug conjugate (ADC), have climbed one step ahead on the ladder of one more milestone by making an effort to fight cancer that goes beyond the ADC's recent limitation criteria. Magnifying the successful meetings and presentations in San Diego at the World ADC Conference with the best ADC companies and the pioneers at CPHI and industry champions in Frankfurt.
Following this, the company thought of taking a step ahead and experimenting with the best for the Sci-tech development. The Defence will be continuing with this smart strategy to become a supplier and promoter of its own Accum® platform technology to the ADC industries. As many of the ADC industries are having a difficult time with toxicity and dosing, also to enhance the drug delivery accurately to cancer cells more smartly and effectively for the best treatment of cancer patients.
The Chief Scientific Officer at Defence Therapeutics, Dr Maxime Parisotto, said, “Many biotech and pharmaceutical companies have engaged in ADC either in the development process or on the market level. Most of these companies struggle in ADC, as it might be toxic for the patients at therapeutic doses. The company’s Accum® technology can globally improve the potential level of any ADCs by mitigating their toxicity, while optimising their tumor targeting and epitope selectivity.”
Defence has shut its studies doors as it has completed and has signalled its ability to improve ADC's potency. The latest comparative study conducted in a mouse xenograft model of HER2-positive breast cancer (JIMT-1 cells), elaborated a ~20-fold peak anti-tumor efficacy with the help of Accum®- Kadcyla than a single Kadcyla® when examined at the same dose (0.5 mg/kg).
The tumor growth took a break in the Accum®- Kadcyla-treated group. This showed a near-complete and continuous response in around 90% of the mice. Whereas, Kadcyla® administered at the same dose (0.5 mg/kg) showed no impactful result on inhibiting tumor growth.
Defence Therapeutics is aligning/partnering with ADC companies to bring a transitional shift in the ADC cancer therapies with its spectacular exclusive Accum® technology platform to be operated on any of the indications and antibodies. The Defence’s technology and a dedicated team are all set to present this smart strategy and ground root an ADC drug delivery powerhouse.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
